Physiological Iron Maintenance in End Stage Renal Disease (ESRD) Subjects by Delivery of Soluble Ferric Pyrophosphate (SFP) Via Hemodialysate: The PRIME Study

Trial Profile

Physiological Iron Maintenance in End Stage Renal Disease (ESRD) Subjects by Delivery of Soluble Ferric Pyrophosphate (SFP) Via Hemodialysate: The PRIME Study

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Ferric pyrophosphate (Primary)
  • Indications Anaemia
  • Focus Therapeutic Use
  • Acronyms PRIME
  • Sponsors Rockwell Medical Technologies
  • Most Recent Events

    • 28 Jun 2017 According to a Rockwell Medical India media release, data from the study will be presented in an oral presentation at the 12th Annual Conference on Nephrology & Urology 2017.
    • 10 Jun 2017 Biomarkers information updated
    • 13 Jul 2015 Results published in a Rockwell Medical Technologies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top